mdl 100240 has been researched along with Cardiovascular Diseases in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Rossi, GP | 1 |
| Agabiti-Rosei, E; Bova, S; Neri, G; Nussdorfer, GG; Pessina, AC; Rizzoni, D; Rossi, GP; Sacchetto, A | 1 |
1 review(s) available for mdl 100240 and Cardiovascular Diseases
| Article | Year |
|---|---|
Dual ACE and NEP inhibitors: a review of the pharmacological properties of MDL 100240.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Benzazepines; Biological Availability; Cardiovascular Diseases; Endopeptidases; Humans; Hypertension; Kidney; Prodrugs; Protease Inhibitors; Pyridines | 2003 |
1 other study(ies) available for mdl 100240 and Cardiovascular Diseases
| Article | Year |
|---|---|
Comparative effects of the dual ACE-NEP inhibitor MDL-100,240 and ramipril on hypertension and cardiovascular disease in endogenous angiotensin II-dependent hypertension.
Topics: Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Animals, Genetically Modified; Aorta; Benzazepines; Blood Pressure; Body Weight; Cardiovascular Diseases; Hypertension; In Vitro Techniques; Male; Neprilysin; Organ Size; Pyridines; Ramipril; Rats; Vasoconstriction | 2002 |